

Individual and Family Plans

Lupron Depot-Ped

Fax back to: (833) 605-4407 Phone: (215) 991-4300

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Patient Name:	Prescriber Name:
Member Number:	Fax: Phone:
Date of Birth:	Office Contact:
Line of Business: 🛛 Exchange - PA	NPI: State Lic ID:
Address:	Address:
City, State ZIP:	City, State ZIP:
Primary Phone:	Specialty/facility name (if applicable):

REQUEST FOR EXPEDITED REVIEW: By checking this box and signing below, I certify that the standard review timeframe may seriously jeopardize the life or health of the enrollee or the enrollee's ability to regain maximum function.

Drug Name:	
Strength:	
Directions / SIG:	

Please attach any pertinent medical history including labs and information for this member that may support approval. Please answer the following questions and sign.		
Q1. Request Type:		
□ Initial		Continuation - Go to 8
Q2. Does the patient have a diagnosis of central precocious puberty (CPP)?		
□ Yes		No
 Q3. For female patients, are all of the following criteria are met: A) Intracranial tumor has been evaluated by appropriate lab tests and diagnostic imaging (e.g., computed tomography [CT] scan, magnetic resonance imaging [MRI]). B) The diagnosis of CPP has been confirmed by a pubertal response to a gonadotropin releasing hormone (GnRH) agonist test or a pubertal level of a third-generation luteinizing hormone (LH) assay. C) The assessment of bone age versus chronological age supports the diagnosis of CPP? 		
□ Yes	□ No	
Q4. For male patients, are all of the following criteria are met: A) Intracranial tumor has been evaluated by appropriate lab tests and diagnostic imaging (e.g., CT scan, MRI).		



Individual and Family Plans

Lupron Depot-Ped

Fax back to: (833) 605-4407 Phone: (215) 991-4300

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

Patient Name:	Prescriber Name:		
 B) The diagnosis of CPP has been confirmed by a pubertal response to a GnRH agonist test or a pubertal level of a third generation LH assay. C) The assessment of bone age versus chronological age supports the diagnosis of CPP. D) The member was less than 9 years of age at the onset of secondary sexual characteristics? 			
□ Yes □ No			
Q5. Is the requested medication being used for pubertal hormonal suppression in an adolescent patient?			
□ Yes	□ No		
 Q6. Does the patient meet all of the following criteria are met: A) The member has a diagnosis of gender dysphoria. B) The member is able to make an informed decision to engage in treatment. C) The member has reached Tanner stage 2 of puberty or greater. D) The member's comorbid conditions are reasonably controlled. E) The member has been educated on any contraindications and side effects to therapy. F) The member has been informed of fertility preservation options? 			
Yes No			
Q7. Is the requested medication being used for g	gender transition?		
□ Yes	□ No		
 Q8. Does the member meet all of the following c A) The member has a diagnosis of gender dysph B) The member is able to make an informed dec C) The member will receive the requested medic hormones. D) The member's comorbid conditions are reaso E) The member has been educated on any contribution of fertility present of the fertility	noria. sision to engage in treatment. cation concomitantly with gender-affirming mably controlled. raindications and side effects to therapy.		



Individual and Family Plans

Lupron Depot-Ped

Fax back to: (833) 605-4407 Phone: (215) 991-4300

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.		
Patient Name:	Prescriber Name:	
Q9. Is the requested medication being prescribed by or in consultation with a provider specialized in the care of transgender youth (e.g., pediatric endocrinologist, family or internal medicine physician, obstetrician-gynecologist) that has collaborated care with a mental health provider for patients less than 18 years of age?		
□ Yes	□ No	
Q10. For continuation, what is the diagnosis?		
 CCP (female) – go to 11 CCP (male) – go to 13 Pubertal hormonal suppression – go to 15 Gender transition – go to 16 		
Q11. Is the female patient currently less than 12 years of age?		
□ Yes	□ No	
Q12. Is the patient currently receiving treatment and is not experiencing treatment failure (e.g., clinical pubertal progression, lack of growth deceleration, continued excessive bone age advancement)?		
□ Yes	□ No	
Q13. Is the male patient currently less than 13 years of age?		
□ Yes	□ No	
Q14. Is the patient currently receiving treatment and is not experiencing treatment failure (e.g., clinical pubertal progression, lack of growth deceleration, continued excessive bone age advancement)?		
□ Yes	□ No	
Q15. Does the patient meet all of the following cr A) The patient has a diagnosis of gender dyspho B) The patient is able to make an informed decis	ria.	



Individual and Family Plans

Lupron Depot-Ped

Fax back to: (833) 605-4407 Phone: (215) 991-4300

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

Patient Name:	Prescriber Name:	
C) The patient has previously reached Tanner st D) The patient's comorbid conditions are reasona E) The patient has been educated on any contra F) Before the start of therapy, the patient has bee	ably controlled. indications and side effects to therapy.	
	□ No	
Q16. Additional Information:		
 Q17. Does the patient meet all of the following criteria: A) The patient has a diagnosis of gender dysphoria. B) The patient is able to make an informed decision to engage in treatment. C) The patient will receive the requested medication concomitantly with gender-affirming hormones. D) The patient's comorbid conditions are reasonably controlled. E) The patient has been educated on any contraindications and side effects to therapy. F) Before the start of therapy, the patient has been informed of fertility preservation options? 		

Prescriber Signature

Date

v2025